Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability.
about
Pharmacokinetic aspects and in vitro-in vivo correlation potential for lipid-based formulationsCritical concentrations in the dilution of oral self-microemulsifying drug delivery systems.Enhanced oral bioavailability of valsartan using a polymer-based supersaturable self-microemulsifying drug delivery system.Dual approach utilizing self microemulsifying technique and novel P-gp inhibitor for effective delivery of taxanes.Preparation and anesthetic properties of propofol microemulsions in rats.Application of mixture experimental design to simvastatin apparent solubility predictions in the microemulsifion formed by self-microemulsifying.Nano composite emulsion for sustained drug release and improved bioavailability.Preparation and in vivo evaluation of a dutasteride-loaded solid-supersaturatable self-microemulsifying drug delivery system.Enhanced dissolution and oral absorption of tacrolimus by supersaturable self-emulsifying drug delivery system.Nanoemulsion-based delivery systems for poorly water-soluble bioactive compounds: Influence of formulation parameters on Polymethoxyflavone crystallizationDevelopment of supersaturatable self-emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs.Hydrotropic polymeric micelles for enhanced paclitaxel solubility: in vitro and in vivo characterizationDevelopment of self-nanoemulsifying drug delivery systems for the enhancement of solubility and oral bioavailability of fenofibrate, a poorly water-soluble drug.Preparation and evaluation of self-nanoemulsifying tablets of carvedilol.Evaluation of a nanoemulsion formulation strategy for oral bioavailability enhancement of danazol in rats and dogs.Extended release felodipine self-nanoemulsifying system.Evaluation of Carbamazepine (CBZ) Supersaturatable Self-Microemulsifying (S-SMEDDS) Formulation In-vitro and In-vivo.Microemulsions as drug delivery systems to improve the solubility and the bioavailability of poorly water-soluble drugs.Metronomic oral paclitaxel shows anti-tumor effects in an orthotopic mouse model of ovarian cancer.Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: A mechanistic basis for utility.Role of excipients in successful development of self-emulsifying/microemulsifying drug delivery system (SEDDS/SMEDDS).Potentials and challenges in self-nanoemulsifying drug delivery systems.Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.Lipid-based formulations and drug supersaturation: harnessing the unique benefits of the lipid digestion/absorption pathway.Advances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevance.Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems.Self-microemulsifying drug delivery system (SMEDDS)--challenges and road ahead.Self-assembled structures formed during lipid digestion: characterization and implications for oral lipid-based drug delivery systems.Theory and practice of supersaturatable formulations for poorly soluble drugs.Polymer-lipid hybrid systems: merging the benefits of polymeric and lipid-based nanocarriers to improve oral drug delivery.Novel dietary lipid-based self-nanoemulsifying drug delivery systems of paclitaxel with p-gp inhibitor: implications on cytotoxicity and biopharmaceutical performance.From nanoemulsions to self-nanoemulsions, with recent advances in self-nanoemulsifying drug delivery systems (SNEDDS).Enhanced dissolution of celecoxib by supersaturating self-emulsifying drug delivery system (S-SEDDS) formulation.Lipid-based oral delivery systems for skin deposition of a potential chemopreventive DIM derivative: characterization and evaluation.Encapsulation and Delivery of Crystalline Hydrophobic Nutraceuticals using Nanoemulsions: Factors Affecting Polymethoxyflavone Solubility.Improved oral bioavailability of poorly water-soluble indirubin by a supersaturatable self-microemulsifying drug delivery system.Application of dissolution/permeation system for evaluation of formulation effect on oral absorption of poorly water-soluble drugs in drug development.Engineering erythrocytes as a novel carrier for the targeted delivery of the anticancer drug paclitaxelEffects of polysorbate 80 on the in-vitro precipitation and oral bioavailability of halofantrine from polyethylene glycol 400 formulations in rats.Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges.
P2860
Q28084784-FC19A807-E9C6-4555-AC6E-AFA6B43433E4Q33514056-F71FF20F-F386-4961-A3EE-7EEDD4AFCA9AQ33674114-F0837564-D523-4AFE-9D47-EF7A812EE9B3Q34206944-FE6F4D50-57E7-4F2B-8544-FDFCBAC10D81Q34393783-C71D2089-5048-4696-9610-622E06229B9CQ34692340-12F9B3EC-6FDF-4731-8CA4-7E9911B42CCFQ35154212-29C2BB3B-6D5A-4FC2-8D45-6367604283D5Q35723500-525E4B68-E9CC-4D37-8961-DD4AB97FD63AQ35981473-CEEF2150-23E2-4DB6-B346-4B13887168C5Q36009014-F2150C6E-1BAD-413D-8C63-D6FBC147B443Q36349701-F0125ADA-3FF0-4A98-83B3-C9507AB58F56Q36868666-A00E41B4-ACA7-421B-91A2-2547772F204BQ37021478-DE1CFAC4-266C-4EE2-948E-C084E52AFB34Q37146180-5863E1C2-3AF7-43BC-80D7-DD15109BD541Q37171319-1DF12AC0-6FB8-41E2-AEA9-728A2740AE74Q37213292-534669A1-39FE-4A6A-AFD5-19F8B7FDE80AQ37268140-D778B8DE-7B47-43E6-BACF-65D323450631Q37702234-7CF8CE1E-98F5-4179-BED6-5DCD562CD6F0Q37717741-4C41B22D-1FE0-4E32-B872-12A0FC56C316Q37802897-A3B25524-BB0B-4BBC-A5E0-10850381BA1EQ37988960-187D5D82-95F5-4617-A8A4-4C56B102F17EQ38041256-4BEB7246-CF40-4CA1-A52F-3089129592C3Q38082728-2E2055D8-BEA0-4511-8EEA-475294E12319Q38119168-16C82B80-A844-425D-B72D-0684A8BBA300Q38167822-ACE1E95B-7D1C-4A18-A9F8-04480E2AD9BDQ38181489-F5D8B2C6-042B-48AA-98CE-49B69A68225BQ38199539-7C9C8ABA-828E-429B-A44B-A9B8FBC25BD9Q38383061-2F9C6257-73D3-4871-9613-34626807AC24Q38411345-9D5F3549-D68E-484E-BA5D-30031DDEA62EQ38729314-8C459BCD-BB19-41A0-80CF-AC674D41C122Q38856512-100F764A-9FD2-4995-A37E-D1974924BFC9Q38916539-33301C98-835A-4A4F-B99C-2B73AB51121BQ39484089-F92FFDE3-3705-4CBC-8A00-6EC22AA06E7CQ39609219-3861A648-13CF-4A38-BB90-C3A375774EF7Q40261316-B4B8F23C-C0C3-46C0-ADA3-91A6C97003F4Q41907224-83E21E69-CABB-48CF-A288-F8DA60056C3BQ42498380-A9ED18E5-A266-417C-9FC1-A821E0726886Q42736840-2096FE84-EA6E-4650-A4F1-391B80BEA4BFQ42932537-EAE059DC-F3D7-4C40-B58C-6B1994D0DE61Q43080152-29CC2A47-0721-4297-8679-874BFE60E797
P2860
Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Development of a supersaturabl ...... improved oral bioavailability.
@en
Development of a supersaturable SEDDS
@nl
type
label
Development of a supersaturabl ...... improved oral bioavailability.
@en
Development of a supersaturable SEDDS
@nl
prefLabel
Development of a supersaturabl ...... improved oral bioavailability.
@en
Development of a supersaturable SEDDS
@nl
P2093
P356
P1476
Development of a supersaturabl ...... improved oral bioavailability.
@en
P2093
Bobby D Rush
Juliane M Bauer
Michael J Hageman
Ming-Shang Kuo
Tiehua Huang
Walter Morozowich
William P Pfund
P304
P356
10.1002/JPS.10511
P407
P577
2003-12-01T00:00:00Z